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Association (CHIRA) data is explored. The advantages and limitations of the CHIRA 
data are described. Results: Although there have been abstract disclosures in 
scientific conferences, a search in PubMed (January 8, 2014) found no manuscripts 
published that presented analyses using CHIRA data. It uses ICD-10 codes and col-
lects cross-sectional data annually from inpatient claims records from sample cit-
ies. Advantages include the availability of demographics, institution, diagnoses, 
medications, service use, hospital stay, insurance type and service cost information 
for a large, diverse local population.  Limitations include the lack of longitudinal 
patient records, incomplete data, the lack of outpatient data and standardized bill-
ing codes, and limited access for research purposes. ConClusions: At present 
claims data in China are relatively difficult to access and to use. However the use 
of claims data for health services research is expected to increase in line with 
planned enhancements to data availability and quality, and the increasing needs 
for RWE by decision makers.
PRM14
Managing Congenital and PediatRiC CaRdiaC SuRgeRy data BaSe: the 
iMPaCt on CliniCal PRaCtiCe and Quality of CaRe
Furnaz S.
Aga Khan University and Hospital, Karachi, Pakistan
objeCtives: To develop a functional and validated database for quality assur-
ance and improving patient outcomes and establishing institutional integ-
rity. Methods: The Cardiothoracic surgery division at the Aga Khan University 
Hospital maintains a computerized database of all the patients undergoing cardiac 
surgery since July 2006. For this study, data of 1236 patients operated between July 
2006 and Dec 2013 was analyzed. Major measures of outcomes included in-hospital 
and 30 day mortality and morbidity outcomes like reopening, sepsis prolong venti-
lation, arrhythmias low cardiac output syndrome. Results: Out of a total of 1236 
heart surgeries, the most common open heart surgeries were VSD 27%, TOF 24% 
were, and 13% were ASD. In closed heart 51% were Modified BT shunts, 17% were 
PDA. The overall 30-day mortality in open heart was 7.0%, and in closed heart it 
was 7.3%. Post-surgery more common  complication  in open heart surgery was 
prolong ventilation which was 39%,arrhythmias 14%,reopenings 11% and sepsis 
5%total morbidity was 29% while in closed heart most common complication 
was prolong ventilation which was 31%, total morbidity was 21%. Readmissions 
after 30 day of Discharge were 8.4% mainly for respiratory infection. Followed 
with 14% lost to follow-ups 85% patients were alive, 0.6% were died at 30 day 
patients follow up. ChAnges depend on dAtAbAse: VSD: on table extubation 
or extubation with 4 hours – minimal morbidity and early discharges. ASD: on 
table extubation. ConClusions: Updated and stringently maintained database 
helped to identify deficiencies, strength and trends of the Pediatric and Congenital 
Cardiac surgery program at our hospital and also to design strategies for continu-
ing improvement in patient care. Also provides scientific evidence for comparing 
results with other institutions of the region and world.
PRM15
develoPMent of a longitudinal national footBall league injuRy 
and injuRy iMPaCtS (l-nfl-iii) dataBaSe
Markowitz J.S.1, Papadopoulos G.2, Markowitz A.3
1Health Data Analytics, Princeton Jct., NJ, USA, 2Emerald Corporate Group P/L, McMahons Point, 
Australia, 3Consultant, San Salvador, El Salvador
objeCtives: Injuries in sports, including professional American football, are a 
major public health problem affecting millions of young and adult athletes around 
the world each year. While most injuries are minor, some end seasons, careers, and 
may even result in long-term disability. No outcomes databases exist that focus 
on injuries in the National Football League (NFL). We sought to develop a database 
that’s longitudinal and includes key injury impact outcomes. Methods: Four years 
of data including information on any player that played 1+ regular season games 
between 2010 and 2013 were adapted from NFL.com, ESPN.com, TSN.com and sev-
eral other reputable online sources. Five different and unique data types, all capable 
of being merged with one another and used in longitudinal analyses, were stored 
as SAS datasets: Player Background (e.g., age, weight, position), Games Played, NFL 
Injury Report, Injured Reserve List, and Schedule and Conditions (e.g., field sur-
face, weather conditions, referee).  Data from the NFL Injury Report and Injured 
Reserve List contain every significant injury to NFL players during the 4-year period 
including concussions, knees, ankles, hamstrings, etc. Injury Impacts include games 
missed due to injuries as well as season- and career-ending injuries. Results: 
Data on 3,193 unique NFL players are included in the database. About 7,700 player-
seasons are captured that cover nearly 91,000 player-games. About 18,500 Injury 
Reports are recorded on these players resulting in more than 6,000 missed games. 
In addition, almost all 959 Injured Reserve List injuries are season-ending and sig-
nificantly raise the risk of ending a player’s career. ConClusions: The L-NFL-III 
database can be a useful tool for epidemiological and outcomes research related to 
injuries in the NFL. In 4-year longitudinal analyses, this database was successful 
in identifying a large number of missed games due to injuries, as well other critical 
outcomes including season- and career-ending injuries.
PRM16
health CaRe dataBaSeS aPPlied to antidePReSSantS uSe in  
aSia-PaCifiC
Milea D.1, Reginald P.2, Saragoussi D.3, Kalita P.4, Verpillat P.5, Azmi S.2
1Lundbeck Singapore Pte Ltd., Singapore, 2Azmi Burhani Consulting, Petaling Jaya, Malaysia, 
3Lundbeck SAS, Issy-les-Moulineaux, France, 4Lundbeck Singapore Pte Ltd, Singapore, 5Lundbeck 
SAS, Issy-les-Moulineaux Cedex, France
objeCtives: Health care databases represent an optimal tool for conducting large 
retrospective epidemiological studies and are largely used in Europe and the US. 
This study is the second phase of an earlier study which qualititatively describes 
databases in Asia Pacific. In this phase, we focused on several countries that have 
large health care databases used for administrative functions namely South 
analysis. The time horizon for each studies ranged from 2-3 months in the RCTs, 
and 1-24 months in the observational studies. No discounting was reported in any 
of the articles. Only one article reported sensitivity analysis. ConClusions: All HE 
studies published were piggy-backed to clinical studies and none utilised HE model-
ling.  None of the HE studies completely fulfilled the standard HE reporting criteria.
ReSeaRCh on MethodS – databases & Management Methods
PRM11
aSSeSSMent of need, develoPMent and iMPleMentation of 
SuPPoRtive ManageMent dataBaSe foR the tReatMent of PoiSoning 
CaSeS in a teRtiaRy CaRe hoSPital
Nikhil B.1, Thunga G.1, Pariti B.2, Varma M.3
1Manipal College of Pharmaceutical Sciences, Manipal University, Manipal, India, 2Manipal 
University, Manipal, India, 3KMC, udupi, India
objeCtives: The main purpose of the present study was to assess the physicians 
need for the development of a supportive management database for the treatment 
of poisoning cases and to implement such a database in the hospital setup based on 
the need of the physicians. Methods: A prospective, observational study was con-
ducted in the emergency department of Kasturba Hospital, Manipal. The study was 
approved by the Institutional Ethics Committee of Kasturba Hospital, Manipal. A 12 
item questionnaire was developed, validated and given to 42 physicians who treated 
acute poisoning cases to assess their need for the development and implementation 
of a supportive management database. Material for the database was prepared after 
conducting an electronic literature search of various existing databases. Results: 
The 12 item questionnaire was given to seven experts for content validation. Out 
of twelve items, one item was excluded from the final questionnaire as it did not 
meet the required value. All 42 (100%) of the physicians believed that a supportive 
management database for poisoning cases in the hospital setup would be really 
helpful. Over 300 articles were referred in the preparation of the material for the 
database. ConClusions: Clinical pharmacists together with physicians who treat 
poisoning cases must work hand in hand in developing institutional guidelines for 
the management of poisoning. Development of such guidelines could reduce the 
complications and mortality which are associated with poisoning cases.
PRM12
evidenCe foR validity of a national PhySiCian and Patient-RePoRted 
SuRvey in China and united KingdoM: the diSeaSe SPeCifiC PRogRaMMe
Babineaux S.M.1, Curtis B.H.1, Holbrook T.2, Liu L.3, Colclough H.4, Piercy J.4
1Eli Lilly & Company, Indianapolis, IN, USA, 2Adelphi Real World, Bollington, UK, 3Eli Lilly Suzhou 
Pharmaceutical Co. Ltd., Shanghai, China, 4Adelphi Real World, Cheshire, UK
objeCtives: Traditional large scale epidemiological surveys used to inform public 
health decision-making have limitations, notably the cost and time to administer 
them and the timeliness of the data, sometimes subject to 5 or more years between 
updates. This analysis aimed to validate a newer survey methodology by comparing 
output with that from two large scale health surveys. Methods: Data were drawn 
from the Adelphi Diabetes Disease Specific Programme (DSP), a cross-sectional sur-
vey of physicians and their patients conducted in China (2012) and United Kingdom 
(UK) (2013). Detailed records for 1662 patients were provided by 200 physicians 
in China. In the UK, 125 physicians provided records for 1237 patients.  Clinical 
and demographic characteristics of the samples were compared with independ-
ent representative national data sources:  a 2007/08 Chinese epidemiology study 
(46,239 patients) and the Health Survey for England 2011 (HSFE), administered to 
10,000 individuals. Variables common to both datasets were compared and tested 
for significant differences. Results: Systolic blood pressure (SBP) and low-density 
lipoprotein (LDL) values from the China DSP were statistically non-different from 
the national survey. There were differences between fasting plasma glucose (137.8 
vs. 158.6); age (56.6 vs. 55.8); male body mass index (BMI) (24.1 vs. 25.2) and high-
density lipoprotein. Comparing the UK DSP with the HSFE, all variables (age, gender, 
smoking status, age at diagnosis (61.5 vs. 63.9), insulin-treated, BMI (31.6 vs. 32.3), 
total cholesterol, HBA1C% (7.768 vs. 7.981), and SBP were non-different. Weeks since 
diagnosis differed - 358 DSP vs. 504 HSFE. ConClusions: Results demonstrate that 
the DSP methodology enables up-to-date representative sampling of treated adult 
patients in Western and Asian populations for national disease burden quantifica-
tion, and treatment pattern and outcomes assessment. A limitation is that sampled 
patients are more recently diagnosed, but there are otherwise only minor differ-
ences in clinical and demographic characteristics.
PRM13
Real WoRld evidenCe in Mainland China: exPeRienCe With the uSe of 
health CaRe ClaiMS data
Yang Y.1, Zhang J.2, Du F.3, Montgomery W.4, Li H.5, Flynn J.A.6
1Eli Lilly Suzhou Pharmaceutical Co., Ltd., Shanghai, China, 2China Health Insurance Research 
Association, Beijing, China, 3Beijing Brainpower Pharma Consulting Co. Ltd., Beijing, China, 4Eli 
Lilly Australia Pty Ltd, West Ryde, Australia, 5Eli Lilly and Company, Indianapolis, IN, USA, 6Eli 
Lilly Japan K.K., Kobe, Hyogo, Japan
objeCtives: The China public health insurance system now covers 95% of the 
population due to efforts to establish universal coverage under three primary gov-
ernment programs (Urban Employee Basic Medical Insurance, Urban Resident Basic 
Medical Insurance, and New Rural Cooperative Medical Scheme).  Data from these 
insurance programs are combined to create the China Health Insurance Association 
(CHIRA) database; the only national claims database in China.  Use of these data 
allow research to examine patients, settings, patterns and outcomes that may dif-
fer from that of RCTs; advancing China’s population-based research and enhanc-
ing the opportunity to apply real world evidence (RWE) in local decision making.  
The use of claims data is relatively uncommon in China. This work explores the 
current and potential use of local claims data as a source of information for RWE 
in China. Methods: The experience of the use of the China Health Insurance 
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PRM19
uSing tRanSMiSSion dynaMiC Model to deteRMine vaCCination 
CoveRage Rate BaSed on eConoMiC BuRden of infeCtiouS diSeaSe: an 
exaMPle of PneuMoCoCCuS vaCCine
Wen Y.W.1, Wu H.1, Fann C.S.J. 2, Chang C.J.3
1Chang Gung University, Kwei Shan, Tao Yuan, Taiwan, 2Academia Sinica, Taipei, Taiwan, 3Chang 
Gung University, Kwei-Shan, Taoyuan, Taiwan
objeCtives: Vaccination would lead to reduce the incidence and mortality of an 
infectious disease and then increase the years of life and productivity for entire 
society. But, determination of vaccination coverage rate is usually not taken its 
economic burden into account. This study aims to use a transmission dynamic 
model (TDM) based on a susceptible-infectious-recovered (SIR) model, a system of 
differential equations, to find optimal vaccination coverage rate based on the eco-
nomic burden of an infectious disease. Methods: Vaccination for pneumococcus 
diseases was used as an example to demonstrate the main purpose. 23-valent pneu-
mococcal polysaccharide vaccines (PPV23) and13-valent pneumococcal conjugate 
vaccines (PCV13) have been shown their cost-effectiveness in elderly and children, 
respectively. Scenarios analysis of PPV23 to the elderly aged 65+ years and PCV13 to 
children 5 years and under was applied to assess the optimal vaccination coverage 
rate based on the economic burden. All epidemiological parameters were derived 
from the Taiwan’s National Health Insurance Research Database, all cost parameter 
were derived from the Taiwan’s Ministry of the Interior and the vaccine efficacy 
was obtained from the literatures. Various vaccination coverage rate, the vaccine 
efficacy and all epidemiological parameters were all substituted into to TDM and 
all differential equations were solved using the fourth-order Runge–Kutta method 
implemented in R Statistical Software. Results: If the he coverage rate of PPV23 for 
the elderly and PCV23 for the children both reach to 50%, the economic burden due 
to pneumococcus disease will be minimized approximately. ConClusions: This 
study provided an alternative perspective from the economic burden of diseases 
to obtain a vaccination coverage rate using the TDM. This will provide valuable 
information for vaccination policy decision makers.
PRM20
uPfRont oveRall SuRvival Modelling in CoMPaRiSon to Real WoRld 
data: lenalidoMide foR the tReatMent of MultiPle MyeloMa 
PatientS in South KoRea
Félix J., Vandewalle B., Almeida J., Valeska A.
Exigo Consultores, Lisbon, Portugal
objeCtives: Decision makers are frequently faced with the question of how realis-
tic are cost-effectiveness models. Overall survival (OS) is a desired clinical trial and 
health technology assessment endpoint but frequently unrealistic or elusive at the 
point of new drugs financing decision. We aim to compare the overall survival from 
lenalidomide treatment in relapsed/refractory multiple myeloma (rrMM) patients 
estimated from modelling clinical trial data in a cost-effectiveness analysis (CEA) 
and compare it with real-word data (RWD) from South Korea. Methods: In this 
CEA of lenalidomide-plus-dexamethasone OS outcomes were indirectly estimated 
using a quantitative relationship between time-to-progression/progression-free-
survival derived with a censored normal weighted Tobit regression model with 
data from a literature review of 153 studies containing 230 treatment arms and 
22,696 MM patients. Real world data was from a retrospective analysis of 110 heavily 
pre-treated patients from 20 hospitals.  These patients were treated with lenalid-
omide-plus-dexamethasone in the Korean patient access program between 2008 
and 2012. Results: The RWD was available for a heavily pre-treated population 
with 76.3% of patients with > 2 previous treatments. For this population, estimated 
median time to progression (TTP) was 7 and 7.4 months in RWD and MM009/010 
clinical trials, respectively. Corresponding predicted Tobit model upfront OS esti-
mates, corrected for baseline characteristics, were 21.3 and 22.2 months. In the RWD 
data from South-Korea the reported median OS was 21 months. Median OS was also 
21.0 months in the equivalent population of the two large, multicenter MM009/010 
randomized phase III trials. ConClusions: This study provides evidence that over-
all survival of Lenalidomide-plus-dexamethasone treatment in relapsed/refractory 
multiple myeloma estimated in a cost-effectiveness analysis is remarkably similar 
to the outcomes observed in real-word patients and points to the value of such 
upfront estimates to decision makers in the absence of mature overall survival data.
PRM21
CoMPaRing the event PRediCtion CaPaBility of the uKPdS68 and hong 
Kong diaBeteS RiSK eQuationS Within a tyPe 2 diaBeteS SiMulation 
Model
McEwan P.1, Ward T.2, Bennett H.2, Bergenheim K.3
1Health Economics and Outcomes Research Ltd, Cardiff, UK, 2Health Economics and Outcomes 
Research Ltd, Monmouth, UK, 3AstraZeneca, Mölndal, Sweden
objeCtives: There is concern over the ability of cardiovascular risk equations to 
reliably predict event incidence across contrasting populations, specifically when 
considering ethnic variation. The UKPDS68 and Hong Kong (HK) risk equations 
have been extensively validated, and are derived from UK and Chinese popula-
tions, respectively. The objective of this study was to compare the predicted incre-
mental event incidence for different diabetes treatments in a Chinese population, 
when using the UKPDS68 and HK risk equations within an established diabetes 
model. Methods: Treatment with SGLT2 inhibitor or sulfonylurea (SU), combined 
with metformin, was modelled in a cohort of 1,000 patients over variable time 
horizons. Baseline clinical inputs and treatment effects utilised in the model were 
obtained from published literature. Treatment effects were applied to the follow-
ing modifiable risk factors: HbA1c, blood pressure, cholesterol and eGFR. Chinese 
life tables were employed to model all-cause mortality. Incidence of both CHD and 
stroke events were compared. Results: Modelled treatment effects corresponded 
to one predictive risk factor contained in each of the HK equations, compared to four 
in each of the UKPDS68 equations.  When comparing treatment with SGLT2 inhibitor 
to SU using the UKPDS68 equations, the incremental incidence of stroke and CHD 
Korea, Taiwan, Australia, Japan, and Singapore. We assessed the use of databases 
in studies relevant to health economics and outcomes research (HEOR) on the 
use of antidepressants. Methods: A literature search was conducted to include 
English language articles in PubMed to identify  database analysis studies  from 
2000-2013. We identified the number of studies from these countries using the 
databases as well as their  topics of focus. These included studies on  prescription 
patterns, resource use and cost of disease. Results: From the countries included 
in the study, Taiwan had the highest number of studies published on HEOR and 
the use of antidepressants. There were very few or no studies from Japan, South 
Korea, Australia and Singapore. The topics ranged from the use of antidepressants, 
prevalence, use among adolescents, and factors associated with persistence or 
early attrition to treatment. Some studies documented the clinical or economic 
impact of continuous treatment. ConClusions: Viewed in the context of the 
earlier study on availability of accessibility of databases, it appears that Taiwan 
has a high degree of usage based on the number of publications found in our 
second phase. This may be due to some advantages in terms of database acces-
sibility, transparency of processes and representativeness of the population. As 
such, for the purpose of research and improving understanding of disease, the 
authors feel that the Taiwan database is a good example especially for countries 
still developing their database capabilities.
ReSeaRCh on MethodS – Modeling Methods
PRM17
Build Model With aSia PaCifiC Region in Mind: Modeling inR ContRol 
in a CoSt-effeCtiveneSS Model foR StRoKe PRevention in atRial 
fiBRillation PatientS
Chen J.1, Wan Y.2, Chen F.2, Lu Z.G.3
1Merck & Co, Inc., North Wales, PA, USA, 2Nanjing Medical University, Nanjing, China, 3Brigham 
and Women’s Hospital, Boston, MA, USA
objeCtives: Patients, physician behaviors, and health systems differ across 
regions. Models without features to account for heterogeneity can’t be readily 
adapted in AP region. Warfarin, the standard care for stroke prevention in atrial 
fibrillation patients, requires routine monitoring of International Normalized Ratio 
(INR). Below or above the target range (2.0-3.0) increases ischemic or hemorrhagic 
events, respectively. Time in therapeutic range (TTR) determines therapeutic 
effectiveness. INR monitoring and increased hemorrhagic risk created barriers 
for broad effective warfarin use in AP region. The mean TTR in US was 66.7%. 
In contrast, the estimate was 36% in China. All existing anticoagulant models, 
mostly Markov-based, have no explicit INR modeling.  To allow for effectiveness 
projections for warfarin in AP settings, our model incorporated an INR mod-
ule. Methods: We adopted a microsimulation approach to accommodate the 
patient heterogeneity and the strong association between a patient’s history and 
future outcomes. An INR control module was built in three steps: a) estimated 
event rates within target INR range, b) probabilistically chose an INR range for a 
patient at each cycle based on the simulated population’s TTR distribution, and 
c) projected event rates at the chosen INR range by incorporating the relative 
risks of INR control effect on events. Inputs were derived from the RE-LY trial, 
published literature and expert opinion. Results: We performed internal vali-
dation by projecting 2-year clinical events using the RE-LY-like TTR distribution 
(22.2% INR< 2.0, 64.4% 2.0≤ INR≤ 3.0 13.4% INR> 3.0), achieving events rates similar 
to those observed in RE-LY. Applying a China-like TTR distribution (59% INR< 2.0, 
36% 2.0≤ INR≤ 3.0, 5% INR> 3.0) increased ischemic event rates while reducing hem-
orrhagic event rates. ConClusions: Explicitly modeling INR control produced 
realistic projections which allowed adaptation of our anticoagulant model to AP 
settings. Proactively incorporating flexible model structure to accommodate het-
erogeneity was an efficient approach to improve model generalizability.
PRM18
StRategieS to oveRCoMe huRdleS in hta aPPRaiSalS aMid liMitationS 
ReSulting fRoM Single-aRM tRial data
Xenakis A.1, Beckerman R.2
1CBPartners, New York City, NY, USA, 2CBPartners, New York, NY, USA
objeCtives: The purpose of this study was to evaluate the barriers that arise in 
constructing strong pharmacoeconomic (PE) submission based on evidence from 
single-arm clinical trials, and to evaluate strategies to overcome them. Methods: 
A set of therapeutics were selected based on the following criteria: oncology indica-
tion with a PE submission for health technology assessment (HTA) review, utilis-
ing single-arm trial data. HTA appraisals in five major markets were considered 
– GBR, CAN, SCT, GER, and FRA. Modelling approaches used in each appraisal were 
enumerated, and HTA body comments on each employed strategy were collected. 
Each identified modelling strategy was evaluated for its likelihood in overcoming 
a negative appraisal across the selected major markets. Results: The PE model 
barriers associated with single-arm trial data included: lack of direct comparison 
with comparator, reliance on surrogate endpoints, and lack of long-term follow-up. 
The techniques employed to address these drawbacks included: comparison with 
historical control, comparison with self-control, comparison with non-responder 
control, comparison with placebo-arm of a published trial, correlation of surro-
gate endpoints to hard outcomes, survival extrapolation methodology (including 
parametric extrapolation and cumulative survival approach). These methods were 
most successful in FRA and CAN, where positive HTA appraisals were awarded 7/8 
and 2/2 times, respectively; and were least successful in GBR and SCT, where posi-
tive HTA appraisals were awarded 1/4 and 2/8 times, respectively. ConClusions: 
Manufacturers may face difficulties when modelling a product’s economic benefit 
based on data from a single-arm trial. While securing a positive HTA appraisal for 
such PE submissions remains difficult, there exist strategies that can help to over-
come identified barriers, which have led to success in major HTA markets – most 
notably FRA and CAN.
